Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection

AIDS

Volumn 14, Issue 7, 2000, Pages 845-852

  Fichtenbaum, Carl J ^a,e   Zackin, Robert ^b   Rajicic, Natasa ^b   Powderly, William G ^a   Joseph Wheat, L ^c   Zingman, Barry S ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

AIDS; Amphotericin B; Candida; Fluconazole; Oral candidiasis; Refractory candidiasis; Resistant candidiasis

Indexed keywords

AMPHOTERICIN B; CD4 ANTIGEN; FLUCONAZOLE;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; STOMACH PAIN; THRUSH; VOMITING; WEIGHT REDUCTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; DRUG RESISTANCE, MICROBIAL; FEMALE; FLUCONAZOLE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034024664     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005050-00011     Document Type: Article

References (42)

1. 1. Gottlieb MS, Schroff R, Schanker HM. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
2. 2. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia. Initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431-1438.
3. 3. Fox R, Neal KR, Leen CLS, Ellis M, Mandal BK. Fluconazole resistant candida in AIDS. J Infect 1991, 22:202-204.
4. 4. Kitchen VS, Savage M, Harris JRW. Candida albicans resistance in AIDS. J Infect 1991, 22:204-205.
5. 5. Willocks L, Leen CLS, Brettle RP, Urquhart D, Russel TB, Milne LJR. Fluconazole resistance in AIDS patients. J Antimicrob Chemother 1991, 28:937-939.
6. 6. Smith D, Boag F, Midgley J, Gazzard B. Fluconazole resistant Candida in AIDS. J Infect 1992, 23:345-346.
7. 7. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993, 17:1018-1021.
8. 8. Heinic GS, Stevens DA, Greenspan D, et al. Fluconazole-resistant Candida in AIDS patients. Oral Surg Oral Med Oral Pathol 1993, 76:711-715.
9. 9. Sanguineti A, Carmichael JK, Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med 1993, 153:1122-1124.
10. 10. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993, 12:911-915.
11. 11. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant Candidosis in an HIV cohort. AIDS 1994, 8:787-792.
12. 12. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994, 19:684-686.
13. 13. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994, 32:2092-2098.
14. 14. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994, 19:687-692.
15. 15. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994, 18:240-242.
16. 16. Horn CA, Washburn RG, Givner LB, Peacock JE, Pegram PS. Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS. AIDS 1995, 9:533-534.
17. 17. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. Clin Infect Dis 1996, 173:219-225.
18. 18. Cartledge JD, Midgley J, Gazzard BG. Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidiosis. J Antimicrob Chemother 1996, 37:275-283.
19. 19. Quereda C, Polanco AM, Giner C, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996, 15:30-37.
20. 20. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in AIDS patients: prevalence and microbiology. Clin Infect Dis 1997, 24:28-34.
21. 21. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. Ann Intern Med 1997, 126:689-696.
22. 22. Heald AE, Cox GM, Schell WA, Bartlett JA, Perfect JR. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 1996, 10:263-268.
23. 23. Cameron ML, Schell WA, Bruch S, Bartlett JA, Waskin HA, Perfect JR. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother 1993, 37:2449-2453.
24. 24. Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994, 8:945-950.
25. 25. Sangeorozan JA, Bradley SF, Xiaogang H, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment and emergence of fluconazole resistance. Am J Med 1994, 97:339-346.
26. 26. Fichtenbaum CJ, Powderly WG. Refractory and resistant mucosal candidiasis in the acquired immunodeficiency syndrome. Clin Infect Dis 1998, 26:556-565.
27. 27. Kwon-Chung KJ, Bennett JE. Principles of antifungal therapy. In: Medical Mycology, Edited by Kwon-Chung KJ, Bennett JE. Philadelphia: Lea & Febiger; 1992:81-102.
28. 28. Dewsnup DH, Stevens DA. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol 1994, 32:389-393.
29. 29. Nguyen MT, Weiss PG, Labarre RC, Wallace MR. Oral amphotericin B in the treatment of oral candidiasis due to azole-resistant Candida species. 32nd Infectious Disease Society of America Meeting, Orlando. September 1994 [Abstract 287].
30. 30. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980, 18:158-163.
31. 31. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin resistant yeast infection in severely immunocompromised patients. Am J Med 1988, 84:826-832.
32. 32. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-T. Villanova, PA: National Committee for Clinical Laboratory Standards; 1995.
33. 33. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother 1998, 42:1382-1386.
34. 34. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution-effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother 1994, 33:1071-1073.
35. 35. Phillips P, Zemcov J, Mahmood W, Montaner JSG, Craib K, Clarke AM. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996, 10:1369-1376.
36. 36. Fessel WJ, Merril KW, Ward D, et al. Itraconazole oral solution for the treatment of fluconazole refractory oropharyngeal candidiasis in HIV-positive patients. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC. January 1997 [Abstract 327].
37. 37. Skiest D, Ward D, Northland A, Reynes J, Greaves W. Treatment of azole-refractory candidiasis in HIV disease. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 1999 [Abstract 1162].
38. 38. Moskovitz B, Wu J, Baruch A, Benken C. Long term safety and efficacy of Itraconazole oral solution for the treatment of fluconazole refractory oropharyngeal candidiasis in HIV-positive patients. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC. January 1997 [Abstract 325].
39. 39. Koletar SL, Weed HG, Ramundo MB. Thrush unresponsive to treatment with fluconazole in HIV-infected patients. First National Conference on Human Retroviruses. Washington DC. January 1993 [Abstract 35].
40. 40. Fichtenbaum CJ, Yiannoutsos C, Holland F, et al. Refractory mucosal candidiasis in advanced HIV infection. Clin Infect Dis 2000, 30: (in press).
41. 41. Martins MD, Lozano-Chiu M, Rex J. Declining rates of symptomatic oropharyngeal candidiasis (OPC), carriage of Candida albicans, and fluconazole resistance (FLU-R) in HIV patients. 37th Meeting of the Infectious Diseases Society of America. Washington DC. September 1997 [Abstract 138].
42. 42. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996, 334:1674-1675.